RAC 5.59% $1.70 race oncology ltd

Industry news, page-973

  1. jd3
    235 Posts.
    lightbulb Created with Sketch. 164
    Ooft

    "When the company stepped up to the fourth dose, they quickly ran into problems as grade 3 and 4 SAEs were observed in patients who received the higher dose of 0.13 mg/kg. This led the trial to drop back down to the third dose level.

    However, this de-escalation has failed to tame the safety problems as the most recent patient given a dose of 0.08 mg/kg experienced respiratory failure and cardiac arrest, possibly related to MGTA-117, which led to death."

    Thankful we have a good understanding Zantrenes safety profile already
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.